Where is Vasthera located?

Vasthera is headquartered in Seoul, South Korea.

Who is the current CEO of Vasthera?

SangWon Kang of Vasthera. They have also founded 1 company.

Where does Vasthera rank among its competitors?

Vasthera ranks 1st amongst 10 active competitors, of which 2 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ambulero, which secured an undisclosed amount in Jun, 2023.

Who are the top competitors of Vasthera?

Vasthera's top competitors include JanOne, Mezzion and Ambulero. Among them, Ambulero secured the most recent funding round in June, 2023.

Vasthera - 2026 Company Profile, Team, Funding & Competitors

Vasthera is a funded company based in Seoul (South Korea), founded in 2017 by SangWon Kang. It operates as a Developer of synthetic therapeutic solutions for vascular hyperplasia. The company has 10 active competitors, including 2 funded and 2 that have exited. Its top competitors include companies like JanOne, Mezzion and Ambulero.

Company Details

VASTHERA is a developer of synthetic therapeutic solutions for vascular hyperplasia. It has developed drug candidates for pulmonary arterial hypertension treatments. It provides drugs for pulmonary arterial hypertension to treat high blood pressure in the lung arteries. It offers therapeutic solutions for several diseases such as In-stent restenosis, cardiac infarction, atherosclerosis, and many more.

Website: www.vasthera.com/
Email ID: *****@vasthera.com
Phone Number: +82 **********

Key Metrics

Founded Year

2017

Location

Seoul, South Korea

Stage

Funding Raised

Investors

Shinhan Venture Investment & 3 more

Ranked

1^st among 10 active competitors

Similar Companies

JanOne & 9 more

View Vasthera's full profile

Vasthera is a funded company. Vasthera has 4 institutional investors.

View details of Vasthera's funding rounds and investors

The founders of Vasthera is SangWon Kang. SangWon Kang is the CEO of Vasthera.

Here are the details of Vasthera's key team members:

SangWon Kang: Founder & CEO of Vasthera.

View details of Vasthera's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vasthera include JanOne, Mezzion and Ambulero. Here is the list of Top 10 competitors of Vasthera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Vasthera 2017, Seoul (South Korea), Funding Raised	Developer of synthetic therapeutic solutions for vascular hyperplasia	-	Shinhan Venture Investment, Premier Partners ... & 2 others	35/100
2nd	JanOne 1983, Las Vegas (United States), Public	Developer of drugs for treating pain, heart disease, and diabetic neuropathy	-	-	35/100
3rd	Mezzion 2002, Seoul (South Korea), Public	Developer of novel therapeutics addressing unmet needs in global markets	-	Shinhan Venture Investment, E&Investment & 1 others	34/100
4th	Ambulero 2019, Miami (United States), Seed	Developer of cell & gene therapies for the treatment of rare vascular disease and critical limb ischemia	$5.5M	Orphinic, NIH	33/100
5th	NangioTx 2015, New York City (United States), Seed	Developer of tissue-regenerative peptides for the treatment of peripheral arterial disease	-	Capital Factory, MassChallenge & 1 others	31/100
6th	Attgeno 2005, Solna (Sweden), Late Stage	Developer of intravenous drug to treat acute high blood pressure	$3.44M	Hadean Ventures	29/100
7th	Liprostin Group 2017, Houston (United States), Funding Raised	Provider of liposome based injections for drug delivery	-	RFG	22/100
8th	Merand Pharmaceuticals 2019, Georgia, Funding Raised	Developer of gene therapies for cardiovascular disorders	-	Tiburon	22/100
9th	K2 Therapies 2020, Los Angeles (United States), Early Stage	Operator of a biopharmaceutical company researching treatments for atherosclerosis and CVD	$25K	-	17/100
10th	BenoBio 2018, Seongnam-si (South Korea), Funding Raised	Developer of drugs based on redox science	-	Korea Investment Holdings	15/100